According to the pharmaceutical and biotechnology industry on the 21st, Pfizer Korea is working on a final application for a vaccine item license. On the 18th of last month, Pfizer Korea applied for a preliminary review of non-clinical and clinical data to the Ministry of Food and Drug Safety.
When an application for a vaccine product license is received, the Ministry of Food and Drug Safety plans to complete the approval review within 60 days.
Pfizer’s vaccine is being promisingly discussed as the first Corona 19 vaccine to be supplied in Korea next month through Cobax Facility, an international project for joint purchase and distribution of vaccines. Earlier, the government has expressed its position that the vaccine supplied by COVAX could be introduced before AstraZeneca’s Corona 19 vaccine.
The Korea Centers for Disease Control and Prevention explained the day before that “the quantity, timing, and type of supply to Korea have not been finally determined,” regarding the supply of vaccines through COVAX. “It is expected that the supply quantity and timing will be determined after the end of January.” did.
Apart from Kovacs, the government has signed a contract to bring in 10 million Pfizer vaccines in the third quarter.
AstraZeneca’s Corona 19 vaccine is expected to be approved for approval as early as late February. On the 4th, AstraZeneca Korea received an application for product permission for the Corona 19 vaccine.
The Ministry of Food and Drug Safety will hold a meeting of the’Corona 19 Vaccine Safety and Effectiveness Verification Advisory Group’ meeting on the 31st of AstraZeneca’s vaccine, where external experts participate, and the results will be disclosed on February 1.
UPI News / Reporter Nam Kyung-sik [email protected]
[저작권자ⓒ UPI뉴스. 무단전재-재배포 금지]